|Bid||9.00 x 1100|
|Ask||11.18 x 1200|
|Day's Range||10.29 - 10.55|
|52 Week Range||5.14 - 16.59|
|Beta (3Y Monthly)||2.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
In conjunction with the new appointments, Beth Seidenberg, M.D., who has served on the company's board of directors since its founding in 2007, will step down from her position. “I am thrilled to welcome Grant and Vicky to our board as we work to execute our Vision 2020, which includes bringing tazemetostat to market for both solid tumors and hematologic malignancies and advancing three new programs into clinical development,” said Robert Bazemore, president and chief executive officer of Epizyme. “Grant’s commercial expertise will be invaluable as we finalize our plans to launch tazemetostat, and Vicky’s past experience as head of biology at Epizyme, along with her extensive drug discovery background, will be critical as we expand our internal pipeline.
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Epizyme (EPZM) delivered earnings and revenue surprises of 0.00% and 424.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The data show that tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in both patients with EZH2 activating mutations and those with wild-type EZH2. The data will be presented today in an oral presentation entitled “Interim update from a Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma” at the International Conference on Malignant Lymphoma (ICML) by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire de Lille, France, an investigator in the Phase 2 trial.
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
Epizyme, Inc. (EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in an oral presentation by Franck Morschhauser, M.D., Ph.D., Centre Hospitalier Régional Universitaire and study investigator, at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.
We can judge whether Epizyme Inc (NASDAQ:EPZM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]
The data will be presented today in an oral presentation entitled “Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients with epithelioid sarcoma” at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting by Silvia Stacchiotti, M.D., Fondazione IRCCS Istituto Nazionale Tumori, Milan, and an investigator in the Phase 2 clinical trial. In July 2017, Epizyme completed enrollment of 62 patients in the epithelioid sarcoma cohort of its Phase 2 trial.